Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP2138 Plus Chemotherapy and Pembrolizumab in Advanced Gastric or GEJ Cancer
NCT07673887Phase 3Recruiting
- Sponsor
- Astellas Pharma
- Start
- Jul 2026
- Primary completion
- Feb 2031
- Countries
- 4
01
Overview
A Phase 3 trial of ASP2138 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Astellas Pharma. Started Jul 2026; status: recruiting.
02
Drugs
ASP2138
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07673887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07673887.